Atlanta, GA – Scibility Media – 10/23/2014.
This article discusses three medical technology/instruments companies: Medical Alarm Concepts Holding, Inc. (OTCPINK: MDHI), AngioDynamics Inc. (NASDAQ: ANGO) and Luminex Corporation (NASDAQ: LMNX)
Medical technology companies are once again on the move and investors are once again looking for the best pool from which to choose. A few do stand out, however. These are the companies that keep their fingers on the pulse of the industry and try to deliver value in from their positions of strength.
Medical Alarm Concepts Holding, Inc. (OTCPINK: MDHI) is one of those companies that are doping their bit to keep the sector interesting. The company recently released its March 31, 2014 10-Q filing to the SEC. In it MDHI reported significant improvements across various sectors of its operations.
The biggest and perhaps most telling stat line concerned the improvements in MDHI’s gross margins. The company reported that gross margins improved from 41% in quarter’s end on March 31, 2013 to 79% in quarter’s end on March 31, 2014.
Medical Alarm Concepts Holding, Inc. (OTCPINK: MDHI) said that gross profit for quarter’s end on March 31, 2014 increased to $194,958 from the year earlier at $74,061. Revenues for the three months ended March 31, 2014 were $246,903, an increase of 38% over the $179,110 recorded for the corresponding period in 2013.
MDHI is making solid progress in establishing its dominance in the space. It’s a position that took the stock to a 12-month high of $1.20 – miles away from its current trading price of .40.
Luminex Corporation (NASDAQ: LMNX) operates at the higher end of the medical technology scale and it too has been making some progress. The company which has a market cap of $893 million has seen marked improvements in its trading performance. The stock hit a 2-week high of $20.96, a move that in part reflects the improved earnings numbers for LMNX. The company reported better than expected Q2 2014 results. Adjusted earnings year-over-year saw a 16.7% improvement for LMNX and has set investors hot on its trail.
AngioDynamics Inc. (NASDAQ: ANGO) is another player in the space that has seen much improved numbers in recent months. 12-month estimates for ANGO’s share price have seen intense coverage coming from some of the top analysts on Wall Street.
ANGO is a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology and the company made a big announcement on October 13, 2014. The big story concerned the company’s elevation to the S&P SmallCap 600 Index and the GICS Life & Health Insurance sub-industry index.
These are three companies that are clear about one thing: growth is the worthy ideal.
Its clarity you don’t see often among medical technology companies so investors should definitely pay attention.
EquiPress.com is a non-advertisement based network (currently in limited release) designed for investors to discover and communicate with publicly traded companies in real-time.
Sign-up for free now to experience the full benefits of EquiPress pre-launch.
Discover and communicate with companies you would otherwise never have seen based on your interests, company news, personalized news feeds, and one-on-one communications with no middle-men nor advertisements. Read our no advertisements pledge.
Can’t find your company on EquiPress? Send us an email to firstname.lastname@example.org and we will contact them for you.
Interested in a one month free trial? Get access to our private investor network, real-time news distribution, automatic disclaimers, corporate analytics, verified public profile, and industry-wide marketing of your corporate news.
Disclosure: EquiPress is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. EquiPress does not hold any equity or financial interest in any publicly traded company. EquiPress provides a uniform subscription based service to all publicly traded companies on a monthly basis at a rate of $495 to provide investor awareness. EquiPress receives only cash compensation from clients. Despite the relationship, EquiPress maintains a neutral stance (nonbiased) on any investment related opinions and exists solely for the purpose of allowing investors to communicate with the publicly traded companies in an effort to establish for themselves investment considerations. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor. Please visit www.equipress.com for complete risks and disclosures.